Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies

[Jm954]

10th Feb 2019

Older age and higher comorbidity burden are associated with poor survival outcomes in patients with chronic CLL. Additionally, chemoimmunotherapy is associated with increased toxicity in elderly patients.

They describe a pooled analysis of these studies that evaluated survival outcomes based on patient‐, disease‐, and treatment‐related factors in patients with CLL receiving ibrutinib.

Limitations of this analysis are the exclusion of patients with severe pre‐existing medical conditions due to study eligibility criteria, and the absence of information on dose adjustments in patients receiving concomitant moderate/strong CYP3A inhibitors or ACs/APs.

Notwithstanding, pooling created subgroups large enough for meaningful comparisons and demonstrated the benefit of ibrutinib versus comparator across a range of factors, reinforcing the benefit/risk profile of ibrutinib in patients with CLL/SLL.

More here: onlinelibrary.wiley.com/doi...

Jackie

[barbkay17]

Please could you explain what comorbidity means ? Barb 17

[Peggy4 in reply to barbkay17]

It means having another illness at the same time. Also where two illnesses sometimes interact making them worse. Hope this makes sense.

Peggy 😀

[barbkay17 in reply to Peggy4]

Thankyou -Didnt look in Dictionary but guesswd it must have been somethinf alig those lines --cheers barb kay

[barbkay17 in reply to barbkay17]

PS Next time I will read my reply thru before pressing Send !!

[Peggy4 in reply to barbkay17]

Ha! I do it all the time. Funny thing is that until you pointed it out I hadn’t noticed!🤣